Cells Treated by In Vitro Fucosylation and Methods of Production and Use Thereof

Patent metadata

Field	Value
Publication number	US-2016331785-A1
Application number	US-201615221196-A
Country	US
Kind code	A1
Filing date	Jul 27, 2016
Priority date	Apr 18, 2003
Publication date	Nov 17, 2016
Grant date	—

Abstract

A population of cells possesses enhanced selectin binding based upon a fucosylated selectin ligand present on a surface thereof. Methods of producing the population of cells, along with therapeutic methods of using the cells, are also disclosed.

First claim

What is claimed is:

1 . An isolated population of cells carrying on their surface a fucosylated selectin ligand, wherein the amount of fucosylated selectin ligand is sufficient to cause at least 75% of the cells in the population to bind to the selectin.

2 . The population of cells of claim 1 , wherein at least 90% of the cells in the population bind to the selectin.

3 . The population of cells of claim 1 , wherein at least 95% of the cells in the population bind to the selectin.

4 . The population of cells of claim 1 , wherein the cells are blood cells.

5 . The population of cells of claim 4 , wherein the cells are leukocytes.

6 . The population of cells of claim 1 , wherein the cells are stem cells.

8 . The population of cells of claim 1 , wherein the cells are produced by a process comprising the step of contacting the population of cells with an α1,3-fucosyltransferase in vitro in the presence of a fucose donor so as to fucosylate at least one glycoprotein on the surface of the population of cells to produce a fucosylated selectin ligand on the surface of the cells.

9 . A composition comprising:
a therapeutically effective amount of the isolated population of cells of claim 1 ; and a pharmaceutically acceptable carrier.

10 . A therapeutic method, comprising the step of:
administering the composition of claim 9 to a subject in need of a treatment involving enhanced binding of the subject's cells to the selectin.

11 . A process of producing a population of cells exhibiting enhanced binding to a selectin, the process comprising the step of:
contacting an isolated population of cells with an α1,3 fucosyltransferase and a fucose donor in vitro, wherein the cells have a glycoprotein on a surface thereof forms a selectin ligand when fucosylated, and wherein said contact results in fucosylation of the glycoprotein and thereby produces a population of fucosylated cells exhibiting enhanced binding to the selectin.

12 . The process of claim 11 , wherein the cells are blood cells.

13 . The process of claim 11 , wherein the blood cells are leukocytes.

14 . The process of claim 11 , wherein the cells are stem cells.

15 . The process of claim 11 , wherein the fucose donor is GDP-fucose.

16 . The process of claim 11 , wherein the α1,3 fucosyltransferase is α1,3-fucosyltransferase III (FTIII).

17 . The process of claim 11 , wherein the α1,3 fucosyltransferase is α1,3-fucosyltransferase IV (FTIV).

18 . The process of claim 11 , wherein the α1,3 fucosyltransferase is α1,3-fucosyltransferase V (FTV).

19 . The process of claim 11 , wherein the α1,3 fucosyltransferase is α1,3-fucosyltransferase VI (FTVI).

20 . The process of claim 11 , wherein the α1,3 fucosyltransferase is α1,3-fucosyltransferase VII (FTVII).

Assignees

• Oklahoma Med Res Found

Inventors

• Xia Lijun
• Mcever Rodger P

Classifications

• A61P7/06

  Antianaemics · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• C12N5/0647

  Haematopoietic stem cells; Uncommitted or multipotent progenitors · CPC title